Programmed death ligand-1 expression and occult lymph node metastasis in non-small cell lung cancer

被引:0
|
作者
Mitsui, Suguru [1 ]
Tanaka, Yugo [1 ]
Jimbo, Naoe [2 ]
Doi, Takefumi [1 ]
Tane, Shinya [1 ]
Hokka, Daisuke [1 ]
Maniwa, Yoshimasa [1 ]
机构
[1] Kobe Univ, Div Thorac Surg, Grad Sch Med, 7-5-2 Kusunoki Cho, Chuou Ku, Kobe, Hyogo 6500017, Japan
[2] Kobe Univ, Dept Diagnost Pathol, Grad Sch Med, Kobe, Japan
关键词
non-small cell lung cancer; occult lymph node metastasis; PD-L1; expression; PD-L1; EXPRESSION; ASSOCIATION; PATHWAY;
D O I
10.1111/1759-7714.14922
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Identifying the preoperative risk factors for lymph node upstaging could contribute to the development of individualized perioperative treatment for patients with non-small cell lung cancer (NSCLC). The current study aimed to evaluate the risk factors for lymph node upstaging, including gene mutation and programmed death ligand-1 expression in patients with resectable NSCLC.Methods Data on the clinicopathological characteristics of patients who underwent lobectomy for clinical N0 NSCLC at our institution were collected. The clinicopathological findings of the pathological N0 and lymph node upstaging groups were then analyzed. Univariate and multivariate analyses were performed to examine the predictive factors for nodal upstaging.Results Of 291 patients, 40 had postoperative nodal upstaging (n = 25, N1; n = 15, N2). Large tumor size and high maximum standardized uptake value were significantly associated with nodal upstaging. The nodal upstaging group had a higher proportion of patients with solid adenocarcinoma and lymphatic, vascular, and pleural invasion than the pathological N0 group. Further, the nodal upstaging group had a higher proportion of patients with positive programmed death ligand-1 expression than the pathological N0 group. Univariate and multivariate analyses showed that tumor size and positive programmed death ligand-1 expression were associated with nodal upstaging.Conclusion The appropriate therapeutic strategy including preoperative treatment and resection should be cautiously considered preoperatively in patients with clinical N0 NSCLC who have large tumors and positive programmed death ligand-1 expression.
引用
收藏
页码:1774 / 1781
页数:8
相关论文
共 50 条
  • [21] Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India
    Vallonthaiel, Archana George
    Malik, Prabhat Singh
    Singh, Varsha
    Kumar, Vinay
    Kumar, Sunil
    Sharma, Mehar Chand
    Mathur, Sandeep
    Arava, Sudheer
    Guleria, Randeep
    Jain, Deepali
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2017, 31 : 56 - 61
  • [22] Erratum: Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
    Jin Sheng
    Wenfeng Fang
    Juan Yu
    Nan Chen
    Jianhua Zhan
    Yuxiang Ma
    Yunpeng Yang
    Yan Huang
    Hongyun Zhao
    Li Zhang
    Scientific Reports, 6
  • [23] Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
    Mino-Kenudson, Mari
    CANCER BIOLOGY & MEDICINE, 2016, 13 (02) : 157 - 170
  • [24] Programmed cell death ligand-1(PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
    Mari Mino-Kenudson
    Cancer Biology & Medicine, 2016, 13 (02) : 157 - 170
  • [25] Programmed Death Ligand-1 (PD-L1) Expression in Operable Non-Small Cell Lung Cancer (NSCLC) by Immunohistochemical Analysis
    Babayeva, Sabina
    Dyatlov, Artem
    Pallavi, Ranjita
    Fanucchi, Michael
    Puccio, Carmelo
    Lafaro, Rocco
    Shakil, Fouzia
    Fallon, John T.
    Zhong, Minghao
    LABORATORY INVESTIGATION, 2016, 96 : 467A - 467A
  • [26] Programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer (NSCLC), results of a single institution
    Slezak, A.
    Toth, E.
    VIRCHOWS ARCHIV, 2018, 473 : S112 - S112
  • [27] Programmed cell death ligand-1(PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
    Mari Mino-Kenudson
    Cancer Biology & Medicine, 2016, (02) : 157 - 170
  • [28] The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population
    Skov, Birgit Guldhammer
    Rorvig, Sara Bird
    Jensen, Thomas Hartvig Lindkaer
    Skov, Torsten
    MODERN PATHOLOGY, 2020, 33 (01) : 109 - 117
  • [29] Programmed Death Ligand-1 (PD-L1) Expression in Operable Non-Small Cell Lung Cancer (NSCLC) by Immunohistochemical Analysis
    Babayeva, Sabina
    Dyatlov, Arteni
    Pallavi, Ranjita
    Fanucchi, Michael
    Puccio, Carmelo
    Lafaro, Rocco
    Shakil, Fouzia
    Fallon, John T.
    Zhong, Minghao
    MODERN PATHOLOGY, 2016, 29 : 467A - 467A
  • [30] Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1
    Dolled-Filhart, Marisa
    Roach, Charlotte
    Toland, Grant
    Stanforth, Dave
    Jansson, Malinka
    Lubiniecki, Gregory M.
    Ponto, Gary
    Emancipator, Kenneth
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (11) : 1243 - 1249